ArticleExperimental and therapeutic medicine2026
Prolonged remission of SAPHO syndrome with low-dose leflunomide: A case report and literature review.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report and literature review describes a 60-year-old woman from Southern Italy, diagnosed with synovitis, acne, pustulosis, hyperostosis and osteitis (SAPHO) syndrome in 2015, who achieved sust ained remission through leflunomide therapy. Initially, the patient presented with severe sternoclavicular pain, osteitis and palmoplantar pustulosis. Following leflunomide initiation, the patient experienced significant clinical improvement, maintaining remission for ~5 years, even after a dose reduction to 20 mg on alternate days. No adverse events were reported during the entire treatment period. This case is contextualized within a concise review of the literature on leflunomide use in SAPHO, highlighting its potential as a long-term, low-dose therapeutic option with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.